Michael Barkoviak, MD
Pulmonary Disease · Saint Louis, MONPI 1609867142
Payments from drug & device makers
Across 811 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Sanofi$922
- Regeneron Healthcare Solutions, Inc.$843
- Grifols USA, LLC$434
- plus $3K from 35 others
What the payments were for
- Food & beverage$13,003100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 364 | $4,291 |
| AstraZeneca | 119 | $2,321 |
| Boehringer Ingelheim | 58 | $1,108 |
| Sanofi | 43 | $922 |
| Regeneron Healthcare Solutions, Inc. | 37 | $843 |
| Grifols USA, LLC | 25 | $434 |
| Mylan Specialty L.p. | 19 | $311 |
| Insmed, Inc. | 13 | $250 |
| Philips North America LLC | 14 | $244 |
| Merck | 10 | $241 |
| Jazz Pharmaceuticals Inc. | 8 | $227 |
| Amgen | 12 | $221 |
| United Therapeutics Corporation | 9 | $198 |
| Genentech USA, Inc. | 11 | $187 |
| Harmony Biosciences LLC | 6 | $174 |
| Baxter Healthcare | 5 | $154 |
| Verona Pharma, Inc. | 10 | $139 |
| Electromed, Inc. | 8 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Novartis | 3 | $61 |
| Resmed Corp | 3 | $60 |
| Pfizer | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Fisher & Paykel Healthcare Inc | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Gilead | 2 | $35 |
| Calliditas Therapeutics US Inc. | 1 | $33 |
| Apria Healthcare LLC | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Noah Medical Corporation | 1 | $23 |
| Sandoz | 1 | $22 |
| Olympus America Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Pulmonx Corporation | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,046 in reported general payments places this provider in the 75th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 744 | $608,746 |
| OfevNintedanib Esylate | 20 | $278,709 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 206 | $158,660 |
| NucalaMepolizumab | 34 | $155,730 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 228 | $131,853 |
| Breo ElliptaFluticasone/Vilanterol | 217 | $100,407 |
| Dupixent SyringeDupilumab | 25 | $93,811 |
| XolairOmalizumab | 26 | $90,514 |
| Dupixent PenDupilumab | 13 | $56,353 |
| SymbicortBudesonide/Formoterol Fumarate | 132 | $38,997 |
| Incruse ElliptaUmeclidinium Bromide | 87 | $35,383 |
| Spiriva RespimatTiotropium Bromide | 41 | $29,439 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $25,306 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 660 | $20,872 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 81 | $20,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $4,291 | $1,032,1191,310 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $1,108 | $347,422133 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,321 | $207,855357 claims |
| Mylan Specialty L.p.Yupelri | $311 | $17,49412 claims |
| MerckDulera | $241 | $8,08817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
- Daniel RosenbluthSaint Louis$903K
- Derek ByersSaint Louis$835K
- Jeffrey AtkinsonSaint Louis$604K
- James KringsSaint Louis$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.